FDA takes Exelixis cancer drug off advisory group agenda, approval date stays Nov. 29

Exelixis Inc.'s experimental cancer drug cabozantinib has been removed from the agenda of a Food and Drug Administration advisory committee meeting, the company said Wednesday, but the drug's potential approval date has not changed. Cabozantinib is the first drug from South San Francisco-based Exelixis (NASDAQ: EXEL) to get to this point in the approval process, but it is unclear whether the FDA's decision to remove it from the agenda of the Nov. 8-9 Oncologic Drugs Advisory Committee meeting ultimately could delay a final FDA decision whether to approve the drug. The FDA's decision date for cabozantinib continues to be Nov. 29.